ArticleFrontiers in oncology2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pemetrexed is approved as a single agent for advanced and metastatic thymoma and thymic carcinoma. In practice, pemetrexed is often given with carboplatin, but the safety and effectiveness of this combination has not been established in either of these rare diseases. Methods: We identified patients with unresectable, recurrent, or metastatic thymoma or thymic carcinoma who were treated with carboplatin/pemetrexed or pemetrexed alone from 2006-2024. Time to disease progression and objective response were determined retrospectively using RECIST 1.1. Median progression-free survival (mPFS) and median overall survival (mOS) were estimated using Kaplan-Meier methodology. Results: We identified 24 patients (14 thymoma; 10 thymic carcinoma), including 8 treated with carboplatin/pemetrexed and 16 with pemetrexed alone. For our combined cohort, mPFS was not reached (NR) with carboplatin/pemetrexed vs. 14.7m with pemetrexed (p=0.27). Among patients with thymoma, mPFS with carboplatin/pemetrexed was NR vs. 15.6m for pemetrexed (p=0.09), while among patients with thymic carcinoma mPFS was 10.9m vs. 14.7m (p=0.88), respectively. At a median follow-up of 49.0m (37m for carboplatin/pemetrexed; 107m for pemetrexed), mOS was NR across all groups. The objective response rate (ORR) was 1/8 (12.5%) vs. 5/16 (31%), and the disease control rate (DCR) was 7/8 (87.5%) vs. 11/16 (69%) with carboplatin/pemetrexed and pemetrexed respectively. Discussion: Carboplatin/pemetrexed was well tolerated and not associated with statistically significant differences in PFS compared to pemetrexed monotherapy in our combined cohort or thymic carcinoma and thymoma subgroups. Carboplatin/pemetrexed demonstrated a numerically longer PFS with encouraging disease control rates particularly in patients with thymoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.